[Antibacterial activity of MT-141 against anaerobic bacteria].
In vitro and in vivo antibacterial activities of MT-141, a new cephamycin, against anaerobic bacteria were compared with those of cefmetazole (CMZ), cefoxitin, cefotaxime, ceftizoxime, latamoxef and cefazolin to obtain the following results. MT-141 showed high activity against a wide variety of anaerobic bacteria including B. fragilis and C. difficile except for Eubacterium lentum, E. aerofaciens and B. furcosus. Antibacterial activity of MT-141 against anaerobic bacteria was almost independent of inoculum size, medium, pH and serum addition. In vitro development of resistance of MT-141 against P. variabilis and B. fragilis was comparable to that of CMZ. Successive parenteral administration of MT-141 into mice did not cause abnormal proliferation of C. difficile. MT-141 showed excellent therapeutic effect against experimental subcutaneous abscess in mice caused by B. fragilis.
D000818:Animals; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D001442:Bacteroides Infections / Q000188:drug therapy; D001441:Bacteroides fragilis / Q000187:drug effects; D015311:Cefmetazole; D002513:Cephamycins / Q000494:pharmacology*; D003015:Clostridium Infections / Q000188:drug therapy; D003016:Clostridium perfringens / Q000187:drug effects; D004352:Drug Resistance, Microbial; D051379:Mice; D009070:Moxalactam / Q000494:pharmacology
D002513:Cephamycins; D015311:Cefmetazole; C046079:cefminox; D009070:Moxalactam